|Videos|July 13, 2022
Available Second-Line Treatments for Transplant-Ineligible R/R DLBCL
Author(s)Grzegorz S. Nowakowski, MD
Dr Grzegorz S. Nowakowski reviews the currently available second-line treatment options for transplant-ineligible R/R DLBCL.
Advertisement
Episodes in this series
Advertisement
Related to this article
Anbal-cel demonstrated a 67.1% complete response rate in relapsed or refractory LBCL in the phase 1/2 CRC01-01 trial, evaluating dual PD-1 and TIGIT knockdown CAR T-cell therapy.
Advertisement
Advertisement
Trending on Targeted Onc
1
DeLLphi-305 Sets a New Standard, and the Bar Is Rising in SCLC
2
Anbal-Cel Demonstrates Clinical Activity in Relapsed LBCL
3
FDA Approves OncoMate MSI Dx For Pembrolizumab in MSI-H Tumors
4
FDA Grants RMAT and Fast Track Status to Prizlon-Cel in R/R LBCL
5